Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

被引:42
|
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Kwon, Mi [3 ]
Perez, Ariadna [4 ]
Parody, Rocio [5 ]
Ferra, Christelle [6 ]
Garcia Cadenas, Irene [1 ]
Herruzo, Beatriz [2 ]
Dorado, Nieves [3 ]
Hernani, Rafael [4 ]
Sanchez-Ortega, Isabel [5 ]
Torrent, Anna [6 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Gregorio Maranon, Hematol Dept, Madrid, Spain
[4] Hosp Clin Univ, Hematol Dept, Madrid, Spain
[5] Bellvitge Hosp, Hematol Dept, Barcelona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; RISK-FACTORS; HEMATOLOGIC MALIGNANCIES; HEMORRHAGIC CYSTITIS; ACUTE-LEUKEMIA; BACTEREMIA; OUTCOMES; DONORS; ADULTS;
D O I
10.1038/s41409-021-01328-4
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in 11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM was 3 months (range 1-30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years, lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM (51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
引用
收藏
页码:2432 / 2444
页数:13
相关论文
共 50 条
  • [1] Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide
    Albert Esquirol
    Maria Jesús Pascual
    Mi kwon
    Ariadna Pérez
    Rocio Parody
    Christelle Ferra
    Irene Garcia Cadenas
    Beatriz Herruzo
    Nieves Dorado
    Rafael Hernani
    Isabel Sanchez-Ortega
    Anna Torrent
    Jorge Sierra
    Rodrigo Martino
    [J]. Bone Marrow Transplantation, 2021, 56 : 2432 - 2444
  • [2] Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Severe Aplastic Anemia
    Bonfim, Carmem
    Arcuri, Leonardo Javier
    Nabhan, Samir
    Seber, Adriana
    Nichele, Samantha
    Moreira Funke, Vaneuza Araujo
    Fernandes, Juliana Folloni
    Daudt, Liane Esteves
    Darrigo, Luiz Guilherme, Jr.
    Melo Rodrigues, Ana Luiza
    Guerino Cunha, Renato Luiz
    Arrais, Celso
    Ribeiro, Andreza Feitosa
    Atta, Elias
    Rodrigues Oliveira, Jose Salvador
    Paz, Alessandra
    Calixto, Rodolfo Froes
    Gomes, Alessandra
    Sa Araujo, Carlos Eduardo
    Colturato, Vergilio A. R., Sr.
    Flowers, Mary E. D.
    Pasquini, Ricardo
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S252 - S252
  • [3] Haploidentical Hematopoietic Stem Cell Transplantation with post-transplant Cyclophosphamide for Osteopetrosis
    Even-Or, Ehud
    Zaidman, Irina
    Stepensky, Polina
    [J]. BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 391 - 391
  • [4] Infections in the first year after Haploidentical Stem Cell Transplantation with post-transplant Cyclophosphamide
    Champ, D.
    Bastos, M.
    Perez-Corral, A.
    Kwon, M.
    Serrano, D.
    Balsalobre, P.
    Anguita, J.
    Pascual, C.
    Laperche, C.
    Gayoso, J.
    Diez-Martin, J. -L.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S153 - S154
  • [5] Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
    Mohty, Razan
    Al Kadhimi, Zaid
    Kharfan-Dabaja, Mohamed
    [J]. HEMATOLOGY, 2024, 29 (01)
  • [6] HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
    Kawachi, Akito
    Sekiguchi, Masahiro
    Watanabe, Kentaro
    Inoue, Shutaro
    Hidaka, Moe
    Matsumoto, Kana
    Sato, Yuya
    Uchiyama, Toru
    Kato, Motohiro
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69
  • [7] Post-transplant cyclophosphamide as a graft versus host prophylaxis in pediatric haploidentical hematopoietic stem cell transplantation - case series
    Wawrzyniak-Dzierzek, Elzbieta
    Gajek, Kornelia
    Gorczynska, Ewa
    Kalwak, Krzysztof
    Ussowicz, Marek
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 : 713 - 714
  • [8] HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PEDIATRIC CANCERS
    Uppuluri, Ramya
    Raj, Revathi
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66
  • [9] Early toxicities following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Pennisi, Martina
    Mussetti, Alberto
    Sciumbata, Veronica
    Perrone, Giulia
    Corradini, Paolo
    [J]. BONE MARROW TRANSPLANTATION, 2018, 53 : 320 - 320
  • [10] Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation
    Fuji, Shigeo
    Nakamae, Hirohisa
    Sugita, Junichi
    Najima, Yuho
    Konishi, Tatsuya
    Tanaka, Takashi
    Nakashima, Yasuhiro
    Nishimoto, Mitsutaka
    Okamura, Hiroshi
    Nakayama, Kazutaka
    Ito, Ayumu
    Yoshimitsu, Makoto
    Hino, Masayuki
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Yakushijin, Kimikazu
    [J]. BONE MARROW TRANSPLANTATION, 2024,